1367TiP - Long-term erlotinib therapy in patients with advanced non-small cell lung cancer (NSCLC): interim analysis of baseline characteristics

Date 29 September 2012
Event ESMO Congress 2012
Session Poster presentation I
Topics Anti-Cancer Agents & Biologic Therapy
Non-Small-Cell Lung Cancer, Metastatic
Presenter Christos Chouaid
Authors C. Chouaid1, R. Gervais2, C. Locher3, D. Moro-Sibilot4, B. Commenges5, S. Chenoufi5
  • 1Pneumologie, Pneumologie, APHP, 75012 - paris/FR
  • 2Oncologie, CAC, 14 - caen/FR
  • 3Pneumologie, Meaux, 77 - meaux/FR
  • 4Pneumologie, CHU grenoble, 38 - grenoble/FR
  • 5France, roche, 92 - neuilly/FR

Abstract

Background

Erlotinib has been shown to improve outcomes in patients with recurrent or progressive NSCLC after platinum based chemotherapy. In this clinical setting, some patients derived long-term benefits from erlotinib treatment with at least 9 months of Progression Free Survival (PFS). The aim of this non-interventional prospective study was to analyze the clinical characteristics of these patients. A secondary objective was to evaluate erlotinib long-term safety.

Patients and methods

Patients with advanced NSCLC with recurrent or progressive NSCLC after platinum based chemotherapy treated for at least 9 months by erlotinib and followed for at least 24 months have been included prospectively. Patients' demographics, clinical and histological characteristics, treatments received before erlotinib initiation, data related to erlotinib therapy (line of treatment, dosage, duration of treatment, tolerability), median PFS, objective response rate, overall survival, safety and quality of life data were recorded.

Results

Between June 2010 and June 2011, 205 patients have been included in 76 French institutions. Patients' characteristics were: mean age, 67.4 ± 10.1 years; Caucasian, 96.5%; ECOG performance status (PS) 0/1/2/3, 39.3/54.6/4.6/1.5 (%); male, 42.9%; current/former/never smokers, 5.9/45.6/39.2 (%); adenocarcinoma, 82.2%; stage IV/IIIB, 83.3/16.7 (%). Among 42 patients tested, 50% presented activating epidermal growth factor receptor (EGFR) mutation. Erlotinib was administered as first/second/third line treatment in 20.5/50.7/22.4 (%) of patients. Since treatment initiation, most frequent reported grade 3/4 toxicities were folliculitis (8.8%) and diarrhea (4.4%).

Conclusion

These are, to our knowledge, the first data reported prospectively of long-responders with advanced NSCLC treated with erlotinib. The long-term benefit of erlotinib according to the results of this interim analysis seems to be more marked in patients with adenocarcinoma, good PS and never or former smokers. Otherwise the benefit seems to be independent of gender. Erlotinib was well tolerated without life-threatening toxicities.

Disclosure

C. Chouaid: In the past 5 years, I received fees for attending scientific meetings, speaking, organizing research from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Hoffman la Roche, Astra Zeneka, Sanofi Aventis, Lilly, Novartis and Amgen.

R. Gervais: In the past 5 years, Radj Gervais received fees for attending scientific meetings, speaking, organizing research or consulting from AstraZeneca, Hoffman la Roche, Astra Zeneka, Sanofi Aventis, Lilly, Novartis and Amgen.

C. Locher: In the past 5 years, Chrystel Locher received fees for attending scientific meetings, speaking, organizing research or consulting from AstraZeneca, Hoffman la Roche, Astra Zeneka, Sanofi Aventis, Lilly, Novartis and Amgen.

D. Moro-Sibilot: In the past 5 years, Denis Moro Sibilot received fees for attending scientific meetings, organizing research or consulting from AstraZeneca, Boehringer Ingelheim, Hoffman la Roche, Astra Zeneka, Sanofi Aventis, Lilly, Novartis and Amgen.

B. Commenges: Commenges B is employed by Roche France.

S. Chenoufi: Chennoufi S is employed by Roche France